title: Anti-thymocyte globulin overcomes the negative impact of HLA mismatching in transplantation from unrelated donors.
abstract: OBJECTIVE
  About one third of patients requiring allogeneic hematopoetic stem cell transplantation (HSCT) would not find a matched sibling or alternative donor. Allogeneic HSCT from matched unrelated and mismatched donors carries an increased risk of graft-vs-host disease (GVHD) and transplant-related mortality (TRM).
  
  
  METHODS
  We used anti-thymocyte globulin (ATG-Fresenius) at a median dose of 90 mg/kg body weight as part of a total body irradiation or busulfan-based conditioning regimen for prevention of serious GVHD. All patients received cyclosporine A and short-course methotrexate. We compared outcomes of 65 recipients of human leukocyte antigen (HLA)-mismatched unrelated grafts and 194 recipients of HLA-matched unrelated grafts. Mismatches involved one or two loci. Both groups were comparable in age, graft source, diagnosis, stage of disease, and conditioning regimen, and differed only in dose of ATG administered.
  
  
  RESULTS
  For matched and mismatched transplants, respectively, there was no significant difference in graft failure (0.5% vs 3%; p = 0.16), in the cumulative incidence of grade II to IV acute GVHD (45% vs 35%; p = 0.14) and no difference in overall chronic GVHD (42% vs 40%; p = 0.68). Estimated overall survival (OS) and disease-free survival (DFS) at 5 years were 55% vs 50% (p = 0.99) and 47% vs 47% (p = 1.0), respectively. The cumulative incidence of relapse and TRM at 5 years were 24% vs 25% (p = 0.63), and 29% vs 27% (p = 0.59), respectively.
  
  
  CONCLUSIONS
  Inclusion of ATG-Fresenius in the conditioning regimen permits HSCT from mismatched unrelated donors without excess TRM and GVHD, resulting in identical OS and DFS of recipients of HLA-matched and HLA-mismatched grafts.
authors.affiliation: Department of Stem Cell Transplantation, University Medical Center Hamburg, Hamburg, Germany. ayuketan@uke.uni-hamburg.de
authors.forename: Francis
authors.initials: F
authors.lastname: Ayuk
authors.forename: Galina
authors.initials: G
authors.lastname: Diyachenko
authors.forename: Tatjana
authors.initials: T
authors.lastname: Zabelina
authors.forename: Jens
authors.initials: J
authors.lastname: Panse
authors.forename: Christine
authors.initials: C
authors.lastname: Wolschke
authors.forename: Thomas
authors.initials: T
authors.lastname: Eiermann
authors.forename: Thomas
authors.initials: T
authors.lastname: Binder
authors.forename: Boris
authors.initials: B
authors.lastname: Fehse
authors.forename: Rudolf
authors.initials: R
authors.lastname: Erttmann
authors.forename: Hartmut
authors.initials: H
authors.lastname: Kabisch
authors.forename: Ulrike
authors.initials: U
authors.lastname: Bacher
authors.forename: Nicolaus
authors.initials: N
authors.lastname: Kröger
authors.forename: Axel R
authors.initials: AR
authors.lastname: Zander
mesh_terms: D000293:Adolescent; D000328:Adult; D000961:Antilymphocyte Serum / Q000627:therapeutic use*; D002648:Child; D002675:Child, Preschool; D016572:Cyclosporine / Q000627:therapeutic use; D018572:Disease-Free Survival; D005260:Female; D005500:Follow-Up Studies; D006086:Graft vs Host Disease / Q000517:prevention & control*; D018380:Hematopoietic Stem Cell Transplantation / Q000379:methods*; D006650:Histocompatibility Testing; D006801:Humans; D007166:Immunosuppressive Agents / Q000627:therapeutic use; D007223:Infant; D007938:Leukemia / Q000628:therapy*; D008297:Male; D008727:Methotrexate / Q000627:therapeutic use; D008875:Middle Aged; D009190:Myelodysplastic Syndromes / Q000628:therapy*; D015996:Survival Rate; D019172:Transplantation Conditioning / Q000379:methods*
chemical_list: D000961:Antilymphocyte Serum; D007166:Immunosuppressive Agents; D016572:Cyclosporine; D008727:Methotrexate